Ionis Pharmaceuticals, Inc. (IONS) Stock Forecast
IONS analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.24 / 5 from 25 analysts
- Price target
- $83.83 average of analyst targets
- Upside to target
- +95.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-1.20
- 52-week range
- $42.38 – $86.50
IONS analyst ratings
25 analystsNumber of analysts at each rating.
IONS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IONS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.92 | −$1.06 | −$0.65 | −$0.61 | −49.6% | 8 |
| Current fiscal year (2026) | −$2.70 | −$3.70 | −$2.12 | −$1.54 | −75.0% | 10 |
| Next fiscal year (2027) | −$1.11 | −$2.47 | $0.60 | −$2.70 | +58.8% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IONS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $186.5M | $160.0M | $225.0M | +18.8% | 19 |
| Current fiscal year (2026) | $919.1M | $783.0M | $1.18B | −2.6% | 24 |
| Next fiscal year (2027) | $1.36B | $1.07B | $2.09B | +48.2% | 24 |
IONS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IONS revenue: reported and forecast
IONS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.84 | −$0.81 | −$0.92 | −$0.92 | −$0.92 | +8.7% | 1 up · 5 down |
| Current fiscal year (2026) | −$2.69 | −$2.62 | −$2.59 | −$2.70 | −$2.70 | +0.6% | 3 up · 0 down |
| Next fiscal year (2027) | −$0.61 | −$1.07 | −$1.05 | −$1.11 | −$1.11 | +82.8% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IONS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IONS beat in 12 of 12.
What analysts expect from IONS
25 analysts cover Ionis Pharmaceuticals; their consensus rating is buy (4.24 on a 1–5 scale, where 5 is a strong buy). The average price target is $83.83, 95.2% above the latest close of $42.94. Analysts expect earnings of −$2.70 per share for 2026, −75.0% from a year earlier. For 2027 the average estimate is −$1.11 per share on revenue of $1.4 billion. Ionis Pharmaceuticals beat the EPS estimate in 12 of the last 12 quarters.
Related: IONS income statement, IONS key metrics, IONS chart. See the IONS stock overview for the latest quote and news.
IONS forecast FAQ
What is Ionis Pharmaceuticals's price target?
The average analyst price target for Ionis Pharmaceuticals is $83.83, 95.2% above the latest close of $42.94.
Is Ionis Pharmaceuticals a buy, hold or sell?
Of 25 analysts covering Ionis Pharmaceuticals, 11 rate it a strong buy, 9 a buy, 5 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ionis Pharmaceuticals's EPS forecast?
Analysts forecast −$2.70 per share for 2026 (range −$3.70 to −$2.12); for 2027 the estimate is −$1.11.
What is Ionis Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $919.1 million, growth of −2.6%; for 2027 it is $1.4 billion.
When does Ionis Pharmaceuticals report earnings?
Ionis Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-1.20.
Does Ionis Pharmaceuticals usually beat earnings estimates?
Ionis Pharmaceuticals reported EPS at or above the analyst estimate in 12 of the last 12 quarters.